GCP Extract May Combat Resistant Prostate Cancer

DAVIS, Calif. Researchers at the University of California Davis found genistein-combined polysaccharide (GCP) may increase the life expectancy of some prostate cancer patients. Their results, published in the article "Enhancing the effectiveness of androgen deprivation in prostate cancer by inducing Filamin A nuclear localization" in Endocrine-Related, detail how the mushroom-supplemented soybean extract may help patients who have not responded to traditional androgen-deprivation therapy (Endocr Relat Cancer. 2012 Nov 9;19(6):759-77).

The study focused on how GCP inhibits cancer cell's survival despite testosterone deprivationthe common treatment for prostate cancer. Based on their findings, the researchers hypothesized patients with weak response to androgen-deprivation therapy may benefit from receiving GCP concurrently.

Ralph de Vere White, UC Davis Comprehensive Cancer Center director and study researcher, said he human clinical trials are the next step in investigation. We want to see up to 75 percent of metastatic prostate cancer patients lower their prostate-specific antigen levels, and GCP holds promise of accomplishing this goal," he said. "If that happens, it would probably be a greater therapy than any drug today."